NSABP C-13
Select A Category

NSABP C-13 (ARGO)

A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients with Stage III Colon Cancer (ARGO)

Protocol Chair: Carmen Allegra, MD

Protocol Officer: Samuel Jacobs, MD

Primary Objective: To determine whether treatment with regorafenib following adjuvant therapy improves disease-free survival (DFS) in patients with Stage IIIB or IIIC colon cancer

Patient Population: Surgically resected Stage III (IIIB or IIIC) colon cancer

Target Accrual: 1,118 patients

Status: Closed to accrual

ClinicalTrials.gov Identifier:  NCT02334077